Elsevier

Neuroscience Letters

Volume 450, Issue 3, 6 February 2009, Pages 332-335
Neuroscience Letters

Cerebrospinal fluid α-synuclein in neurodegenerative disorders—A marker of synapse loss?

https://doi.org/10.1016/j.neulet.2008.11.015Get rights and content

Abstract

The association of α-synuclein (α-syn) neuropathology with Parkinson's disease (PD) and several related disorders has led to an intense research effort to develop cerebrospinal fluid (CSF)- or blood-based α-syn biomarkers for these types of diseases. Recent studies show that α-syn is present in CSF and possible to measure using enzyme-linked immunosorbent assay (ELISA). Here, we describe a novel ELISA that allows for quantification of α-syn in CSF down to 50 pg/mL. The diagnostic value of the test was assessed using CSF samples from 66 Alzheimer's disease (AD) patients, 15 PD patients, 15 patients with dementia with Lewy bodies (DLB) and 55 cognitively normal controls. PD and DLB patients and controls displayed similar CSF α-syn levels. AD patients had significantly lower α-syn levels than controls (median [inter-quartile range] 296 [234–372] and 395 [298–452], respectively, p < 0.001). Moreover, AD patients with mini-mental state examination (MMSE) scores below 20 had significantly lower α-syn than AD patients with MMSE scores of 20 or higher (p = 0.02). There was also a tendency towards a negative correlation between α-syn levels and disease duration in the AD group (r = −0.247, p = 0.06). Altogether, our results speak against CSF α-syn as a reliable biomarker for PD and DLB. The lower α-syn levels in AD, as well as the association of α-syn reduction with AD severity, approximated by MMSE, suggests that it may be a general marker of synapse loss, a hypothesis that warrants further investigation.

Section snippets

Acknowledgements

This study was supported by grants from the Swedish Research Council (projects 2006–6227 [HZ] and 2006–2740 [KB]), the Alzheimer's Association (project NIRG-08-90356 [HZ]), the Sahlgrenska University Hospital, the Göteborg Medical Society, Stiftelsen för Gamla Tjänarinnor, the Alzheimer Foundation, Sweden, the Åke Wiberg Foundation, Gun och Bertil Stohnes Stiftelse and Tore Nilsons Stiftelse för Medicinsk Forskning.

References (39)

  • E. Vanmechelen et al.

    Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization

    Neurosci. Lett.

    (2000)
  • N. Andreasen et al.

    Cerebrospinal fluid beta-amyloid(1-42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease

    Arch. Neurol.

    (1999)
  • APA (American Psychiatric Association), Diagnostic and Statistical Manual of Mental Disorders, third ed., revised ed.,...
  • M. Baba et al.

    Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies

    Am. J. Pathol.

    (1998)
  • R. Barbour et al.

    Red blood cells are the major source of alpha-synuclein in blood

    Neurodegener. Dis.

    (2008)
  • H. Bazin

    Rat Hybridomas and Rat Monoclonal Antibodies

    (1990)
  • A.C. Belin et al.

    Parkinson's disease: a genetic perspective

    FEBS J.

    (2008)
  • K. Blennow et al.

    Synaptic pathology in Alzheimer's disease: relation to severity of dementia, but not to senile plaques, neurofibrillary tangles, or the ApoE4 allele

    J. Neural. Transm.

    (1996)
  • K. Blennow et al.

    Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease?

    Mol. Chem. Neuropathol.

    (1995)
  • Cited by (189)

    View all citing articles on Scopus
    View full text